Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies
Hydroxamate-based histone deacetylase inhibitors (Hb-HDACIs), such as vorinostat, belinostat and panobinostat, have been previously shown to have a wide range of activity in hematologic malignancies such as cutaneous T-cell lymphoma and multiple myeloma. Recent data show that they synergize with a v...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2013-07-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2072-6694/5/3/919 |
| _version_ | 1797715903960317952 |
|---|---|
| author | Marinella Zilli Laura Iezzi Felice Simiele Antonino Grassadonia Pasquale Cioffi Clara Natoli |
| author_facet | Marinella Zilli Laura Iezzi Felice Simiele Antonino Grassadonia Pasquale Cioffi Clara Natoli |
| author_sort | Marinella Zilli |
| collection | DOAJ |
| description | Hydroxamate-based histone deacetylase inhibitors (Hb-HDACIs), such as vorinostat, belinostat and panobinostat, have been previously shown to have a wide range of activity in hematologic malignancies such as cutaneous T-cell lymphoma and multiple myeloma. Recent data show that they synergize with a variety of cytotoxic and molecular targeted agents in many different solid tumors, including breast, prostate, pancreatic, lung and ovarian cancer. Hb-HDACIs have a quite good toxicity profile and are now being tested in phase I and II clinical trials in solid tumors with promising results in selected neoplasms, such as hepatocarcinoma. This review will focus on their clinical activity and safety in patients with advanced solid neoplasms. |
| first_indexed | 2024-03-12T08:14:42Z |
| format | Article |
| id | doaj.art-40d51c8cbf83441cb777f306de5be415 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-12T08:14:42Z |
| publishDate | 2013-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-40d51c8cbf83441cb777f306de5be4152023-09-02T18:59:17ZengMDPI AGCancers2072-66942013-07-015391994210.3390/cancers5030919Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid MalignanciesMarinella ZilliLaura IezziFelice SimieleAntonino GrassadoniaPasquale CioffiClara NatoliHydroxamate-based histone deacetylase inhibitors (Hb-HDACIs), such as vorinostat, belinostat and panobinostat, have been previously shown to have a wide range of activity in hematologic malignancies such as cutaneous T-cell lymphoma and multiple myeloma. Recent data show that they synergize with a variety of cytotoxic and molecular targeted agents in many different solid tumors, including breast, prostate, pancreatic, lung and ovarian cancer. Hb-HDACIs have a quite good toxicity profile and are now being tested in phase I and II clinical trials in solid tumors with promising results in selected neoplasms, such as hepatocarcinoma. This review will focus on their clinical activity and safety in patients with advanced solid neoplasms.http://www.mdpi.com/2072-6694/5/3/919hydroxamate-based histone deacetylase inhibitorshistone deacetylase inhibitorsvorinostatbelinostatpanobinostatpracinostatabexinostatresminostat |
| spellingShingle | Marinella Zilli Laura Iezzi Felice Simiele Antonino Grassadonia Pasquale Cioffi Clara Natoli Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies Cancers hydroxamate-based histone deacetylase inhibitors histone deacetylase inhibitors vorinostat belinostat panobinostat pracinostat abexinostat resminostat |
| title | Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies |
| title_full | Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies |
| title_fullStr | Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies |
| title_full_unstemmed | Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies |
| title_short | Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies |
| title_sort | role of hydroxamate based histone deacetylase inhibitors hb hdacis in the treatment of solid malignancies |
| topic | hydroxamate-based histone deacetylase inhibitors histone deacetylase inhibitors vorinostat belinostat panobinostat pracinostat abexinostat resminostat |
| url | http://www.mdpi.com/2072-6694/5/3/919 |
| work_keys_str_mv | AT marinellazilli roleofhydroxamatebasedhistonedeacetylaseinhibitorshbhdacisinthetreatmentofsolidmalignancies AT lauraiezzi roleofhydroxamatebasedhistonedeacetylaseinhibitorshbhdacisinthetreatmentofsolidmalignancies AT felicesimiele roleofhydroxamatebasedhistonedeacetylaseinhibitorshbhdacisinthetreatmentofsolidmalignancies AT antoninograssadonia roleofhydroxamatebasedhistonedeacetylaseinhibitorshbhdacisinthetreatmentofsolidmalignancies AT pasqualecioffi roleofhydroxamatebasedhistonedeacetylaseinhibitorshbhdacisinthetreatmentofsolidmalignancies AT claranatoli roleofhydroxamatebasedhistonedeacetylaseinhibitorshbhdacisinthetreatmentofsolidmalignancies |